Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- XORTX Therapeutics Inc.XORTX Re-Engages Investor Relations ProgramXORTX Therapeutics Inc. ("XORTX" or the “Company”) announces that, following completion of its previously announced voluntary delisting from the TSX Venture Exchange, XORTX has re-engaged IR Agency LLC pursuant to a consulting agreement providing for investor relations and marketing services on substantially the same terms previously disclosed by the Company in its news releases dated May 19, 2026 and August 28, 2026.
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 4,200 shares of its common stock to two new employees. These stock options are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the “Inducement Plan”). The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to their entering into employment with Seres pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan was adopted by Seres’ board of directors in December 2022. The stock options have an exercise price of $5.72 per share. Each option will vest as to 25% of the total number of shares subject to the option on the first anniversary of the individual’s date of hire and as to 6.25% of the total number of shares subject to the option upon completion of each three full months of service to the Company thereafter.
- Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options
- Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual MeetingInhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company") today highlighted several important developments disclosed in its Quarterly Report on Form 10-Q filed August 14, 2026, and encouraged stockholders and other interested parties to review the filing for a more complete discussion of the Company’s progress.
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZPomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateApnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update.
- CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin SyndromeFDA grants Rare Pediatric Disease Designation to QRX003 for Peeling Skin Syndrome, Quoin's second RPD and a potential second Priority Review Voucher
- GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic PillarsNew whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection
- Anitoa Systems, LLCAnitoa Announces Secure Cloud Connectivity for its Portable qPCR Instruments, Unlocking Advanced Biosurveillance and AI IntegrationAnitoa Systems, LLC., a Silicon Valley biotechnology company and market leader in rapid, portable molecular testing hardware, today announced a major advancement in point-of-care molecular testing: the integration of comprehensive cloud...
- MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - RGRD LawThe case alleges Regeneron and its top executives made false and/or misleading statements to investors.
- Alebund PharmaceuticalsAlebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA NephropathyAlebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and Drug Administration (FDA) of its...
- Lakewood-Amedex Biotherapeutics Inc.Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceLakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,...